Cargando…
1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico
BACKGROUND: Tuberculosis (TB) is the leading cause of death from a single infectious agent. Latent tuberculosis infection (LTBI) is defined as TB infection without clinical symptoms or microbiological evidence. LTBI is a risk factor to later development of active TB. COVID-19 pandemic represents an...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677184/ http://dx.doi.org/10.1093/ofid/ofad500.1714 |
_version_ | 1785150070188933120 |
---|---|
author | Montiel, Santiago Valente-Acosta, Benjamin |
author_facet | Montiel, Santiago Valente-Acosta, Benjamin |
author_sort | Montiel, Santiago |
collection | PubMed |
description | BACKGROUND: Tuberculosis (TB) is the leading cause of death from a single infectious agent. Latent tuberculosis infection (LTBI) is defined as TB infection without clinical symptoms or microbiological evidence. LTBI is a risk factor to later development of active TB. COVID-19 pandemic represents an emerging infectious disease. Immunosuppressants as corticoids and tocilizumab are the standard of care of critically ill COVID-19 patients. Those drugs have previously been shown to increase the risk of developing active TB, especially in patients with latent TB. [Figure: see text] METHODS: We conduct a cross-sectional study to determine the prevalence of latent tuberculosis infection, through QuantiFERON, in patients who have been hospitalized with severe or critical COVID-19 at the ABC Medical Center in Mexico City-Mexico, from March 2020 to March 2021. RESULTS: From 1174 records reviewed, a total of 503 patients who have a QuantiFERON® test were included. The prevalence of LTBI in hospitalized patients with severe or critical COVID-19 in our hospital was 10.1% (n=51). Of the total of patients with a diagnosis of LTBI, 82.3% had severe disease and 17.6% had critical illness requiring invasive mechanical ventilation (IMV) and 42 (82%) received corticosteroids and 29 (57%) received tocilizumab. CONCLUSION: To the best of our knowledge this is the first report that depict the LTBI prevalence in a cohort of severe and critical COVID-19 patients in a Lower-Middle Income Country. Our prevalence was lower than previously reported global prevalence of LTBI. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-10677184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106771842023-11-27 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico Montiel, Santiago Valente-Acosta, Benjamin Open Forum Infect Dis Abstract BACKGROUND: Tuberculosis (TB) is the leading cause of death from a single infectious agent. Latent tuberculosis infection (LTBI) is defined as TB infection without clinical symptoms or microbiological evidence. LTBI is a risk factor to later development of active TB. COVID-19 pandemic represents an emerging infectious disease. Immunosuppressants as corticoids and tocilizumab are the standard of care of critically ill COVID-19 patients. Those drugs have previously been shown to increase the risk of developing active TB, especially in patients with latent TB. [Figure: see text] METHODS: We conduct a cross-sectional study to determine the prevalence of latent tuberculosis infection, through QuantiFERON, in patients who have been hospitalized with severe or critical COVID-19 at the ABC Medical Center in Mexico City-Mexico, from March 2020 to March 2021. RESULTS: From 1174 records reviewed, a total of 503 patients who have a QuantiFERON® test were included. The prevalence of LTBI in hospitalized patients with severe or critical COVID-19 in our hospital was 10.1% (n=51). Of the total of patients with a diagnosis of LTBI, 82.3% had severe disease and 17.6% had critical illness requiring invasive mechanical ventilation (IMV) and 42 (82%) received corticosteroids and 29 (57%) received tocilizumab. CONCLUSION: To the best of our knowledge this is the first report that depict the LTBI prevalence in a cohort of severe and critical COVID-19 patients in a Lower-Middle Income Country. Our prevalence was lower than previously reported global prevalence of LTBI. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677184/ http://dx.doi.org/10.1093/ofid/ofad500.1714 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Montiel, Santiago Valente-Acosta, Benjamin 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico |
title | 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico |
title_full | 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico |
title_fullStr | 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico |
title_full_unstemmed | 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico |
title_short | 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico |
title_sort | 1886. prevalence of latent tb infection among critically ill covid-19 population in a tertiary teaching hospital in mexico |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677184/ http://dx.doi.org/10.1093/ofid/ofad500.1714 |
work_keys_str_mv | AT montielsantiago 1886prevalenceoflatenttbinfectionamongcriticallyillcovid19populationinatertiaryteachinghospitalinmexico AT valenteacostabenjamin 1886prevalenceoflatenttbinfectionamongcriticallyillcovid19populationinatertiaryteachinghospitalinmexico |